| Study | Exclusion reasons | Rmk | Reference |
|---|---|---|---|
| Hernandez-Nieto, 2017 | EXCLUDED: Study on the efficacy of infertility treatments (with or without SSRIs) including the miscarriage outcome that is studied as an efficacy criteria rather than a safety one. => Not reported here. |
Hernandez-Nieto C Fertil Steril 2017;108:973-979 10.1016/j.fertnstert.2017.08.040 |
|
| Croen (Controls unexposed, sick), 2011 |
Croen LA Arch Gen Psychiatry 2011;68:1104-12 10.1001/archgenpsychiatry.2011.73 |
||
| Evans-Hoeker, 2018 | EXCLUDED: Study on the efficacy of infertility treatments (with or without SSRIs) including the miscarriage outcome that is studied as an efficacy criteria rather than a safety one. => Not reported here. |
Evans-Hoeker Fertil Steril 2018; 109:879-887 10.1016/j.fertnstert.2018.01.029 Evans-Hoeker, E.A. Fertil. Steril. 2017; 108:e298-. 10.1016/j.fertnstert.2017.07.882 |
|
| Joseph, 2015 |
Joseph Paediatr Perinat Epidemiol 2015; 29:220-31 10.1111/ppe.12190 |
||
| Friedman, 2009 | EXCLUDED: Study on the efficacy of infertility treatments (with or without SSRIs) including the miscarriage outcome that is studied as an efficacy criteria rather than a safety one. => Not reported here. |
Friedman Fertil Steril 2009; 92:1312-1314 10.1016/j.fertnstert.2009.03.060 |
|
| Zhou, 2018 | |||
| Shah, 2020 | EXCLUDED: antidepressant studied as a whole without distinction between class/substances (and SSRI < 90% of all antidepressants). |
Shah J Perinatol 2020; 40:1025-1030 10.1038/s41372-020-0644-y |
|
| Ramos, 2010 | inadequate or absent control group | EXCLUDED: analysis according to trimester of pregnancy, thus a woman not exposed during the trimester of interest could be exposed during an other trimester of pregnancy. => Inadequate control group. |
Ramos The Canadian Journal of Psychiatry 2010; 55:643-652 10.1177/1756283X10363751 |
| Cole, 2007 | inadequate or absent control group | EXCLUDED: control group was exposed to other antidepressants (NOS), probably with Selective serotonin reuptake inhibitors (SSRIs), which are not an adequate comparison group for Paroxetine which is also a SSRI. Overlapping of Cole 2006 with Cole 2007. |
Cole Pharmacoepidemiol Drug Sa F 2006;15(51):S6.Abstract. Cole JA Pharmacoepidemiol Drug Saf 2007;16:1075-85 10.1002/pds.1463 |
| Bérard (Controls exposed to SNRI or SSRI other than Paroxetine), 2007 | inadequate or absent control group | EXCLUDED: non exposed group: exposed to i) SSRI other than Paroxetine; ii) or non-SSRI antidepressants (venlafaxine (37%) or amitriptyline (33%)), which are not considered as relevant control groups. Overlapping: Bérard 2016: abstract of Bérard 2017. |
Bérard Birth Defects Res A Clin Mol Teratol. 2006;76:335. Abstract Bérard A Birth Defects Res B Dev Reprod Toxicol 2007;80:18-27 10.1002/bdrb.20099 |
| Bérard (Controls exposed to SNRI or SSRI other than Paroxetine), 2007 | inadequate or absent control group | EXCLUDED: non exposed group: exposed to i) SSRI other than Paroxetine; ii) or non-SSRI antidepressants (mainly venlafaxine (37%) or amitriptyline (33%)), which are not considered as relevant control groups. |
Bérard A Birth Defects Res B Dev Reprod Toxicol 2007;80:18-27 10.1002/bdrb.20099 |
| Molenaar, 2020 | inadequate or absent control group | EXCLUDED: study of Dose-effect of maternal serotonin reuptake inhibitor (SSRI and Venlafaxine). All pregnant women exposed to SRI. No adequate control group. |
Molenaar J Affect Disord 2020; 267:57-62 10.1016/j.jad.2020.02.003 |
| Warburton, 2010 | inadequate or absent control group | EXCLUDED: ‘Neonates SSRI-exposed in the last 14 days (L14) of gestation were compared with infants who had gestational exposure, but not during the last 14 days (NL14)’ => all pregnancies exposed to SSRI. => No adequate control group. |
Warburton Acta Psychiatr Scand 2010; 121:471-9 10.1111/j.1600-0447.2009.01490.x |
| Goldstein, 1997 | inadequate or absent control group | EXCLUDED: no control group (authors only mentioned 'These rates are consistent with those found in historic assessment' without other details). |
Goldstein Obstet Gynecol 1997; 89:713-8 10.1016/s0029-7844(97)00070-7 |
| Goldstein, 1995 | inadequate or absent control group | EXCLUDED: all pregnant women exposed to fluoxetine => no control group. |
Goldstein J Clin Psychopharmacol 1995; 15:417-20 10.1097/00004714-199512000-00005 |
| Sit, 2011 | inadequate or absent control group | EXCLUDED: all pregnant women received SRI therapy (sertraline-9, venlafaxine-2, escitalopram-2, citalopram-1, nortriptyline-1, fluvoxamine-1 and fluoxetine-5) => no adequate control group. |
Sit J Clin Psychiatry 2011; 72:994-1001 10.4088/JCP.10m06461 |
| Huybrechts, 2020 | inadequate or absent control group | EXCLUDED: potential control groups are exposed to 1) Venlafaxine, or 2) Duloxetine or 3) Unexposed to Dulotexine (but it could be exposed to SSRI) => no adequate control group. | |
| Casper, 2011 | inadequate or absent control group | EXCLUDED: all infants prenatally exposed to selective serotonin reuptake inhibitor (SSRI) antidepressants, during specific trimesters of pregnancy => No adequate control group. |
Casper Psychopharmacology (Berl) 2011; 217:211-9 10.1007/s00213-011-2270-z |
| Klinger, 2011 | inadequate or absent control group | EXCLUDED: all infants prenatally exposed to selective serotonin reuptake inhibitor (SSRI) antidepressants, with analysis according to neonatal abstinence symptoms at birth or not => No adequate control group. | |
| Park, 2016 | inadequate or absent control group | EXCLUDED: incidence of QTcB prolongation not reported for healthy control group. No adequate control group. |
Park Expert Opin Drug Saf 2016; 15:1013-9 10.1080/14740338.2016.1199681 |
| Hendrick, 2003 | inadequate or absent control group | EXCLUDED: all pregnancies exposed to Selective serotonin reuptake inhibitors (SSRIs). |
Hendrick Am J Obstet Gynecol 2003; 188:812-5 10.1067/mob.2003.172 |
| Forsberg, 2014 | inadequate or absent control group | EXCLUDED: all pregnancies exposed to antidepressants (>90% of selective serotonin reuptake inhibitors (SSRI)). |
Forsberg PLoS One 2014; 9:e111327 10.1371/journal.pone.0111327 |
| Kieviet, 2015 | inadequate or absent control group | EXCLUDED: all pregnancies exposed to a selective serotonin reuptake inhibitors (SSRIs), serotonin noradrenaline reuptake inhibitor (SNRI) or noradrenergic and specific serotonergic antidepressant (NaSSA) => No adequate control group. | |
| Cavusoglu, 2021 | inadequate or absent control group | EXCLUDED: all pregnant women exposed to antidepressants. Authors did not considered a comparator group (unexposed) => No adequate control group. |
Cavusoglu, T. J. Pak. Med. Assoc. 2021; 71:281-. 10.47391/JPMA.805 |
| Newport - SSRI, 2016 | inadequate or absent control group | Most study participants were treated with at least 1 psychotropic agent during pregnancy (n = 607, 88.5%) with antidepressant exposure the most frequent (n=489, 71.3%) => Non exposed women included a large part of SNRI exposures. |
Newport J Clin Psychiatry 2016; 77:1538-1545 10.4088/JCP.15m10506 |
| Kalin, 2019 | inadequate or absent control group | EXCLUDED: all pregnancies exposed to antidepressant (SSRI or SNRI or Bupropion), but data on safety outcomes (admission in neonate intensive care unit) only available for fluoxetine => No adequate control group. |
Kalin, M. Biol. Psychiatry 2019; 85:S319-. 10.1016/j.biopsych.2019.03.809 |
| Tokariev, 2022 | inadequate or absent control group | EXCLUDED: cognitive development only assessed for the serotonin reuptake inhibitors (SRI) babies => No adequate control group. |
Tokariev Front Neurosci 2022; 16:803708 10.3389/fnins.2022.803708 |
| Giorgetti, 2020 | inadequate or absent control group | EXCLUDED: all pregnancies treated with SSRIs/SNRIs => No adequate control group. |
Giorgetti, F. Eur. Neuropsychopharmacol. 2020; 40:S60-. 10.1016/j.euroneuro.2020.09.083 |
| Kelly,, 2015 | inadequate or absent control group | EXCLUDED: 'All patients using SSRIs at time of delivery' => No adequate control group. |
Kelly, J. Am. J. Obstet. Gynecol. 2015; 212:S321-. 10.1016/j.ajog.2014.10.857 |
| Dao, 2023 | inadequate or absent control group | EXCLUDED: comparison of outcomes after prenatal exposure to SSRIs versus Trazodone (for which little data is available on the safety) => No adequate control group. |
Dao J Clin Psychopharmacol 2023; 43:12-19 10.1097/JCP.0000000000001630 |
| Esen, 2022 | inadequate or absent control group | EXCLUDED: Data only available for SSRI versus active treatment (SNRI or TCA or other antidepressants). |
Esen Epidemiology 2022; 33:581-592 10.1097/EDE.0000000000001494 |
| Damer, 2024 | inadequate or absent control group | EXCLUDED: All pregnant women exposed to psychotropics (atypical antipsychotic drugs, SSRI, Tricyclic Antidepressants (TCA), benzodiazepines, and different combinations) => No adequate control group. |
Damer Gen Hosp Psychiatry 2024; 90:76-83 10.1016/j.genhosppsych.2024.06.015 |
| Jovin, 2023 | inadequate or absent control group | EXCLUDED: Case-series of neonatal abstinence syndrome (NAS) without adequate control group (no control group without exposure nor control group without NAS). |
Jovin, V.M. Heroin Addict. Relat. Clin. Probl. 2023; 25:21-. |
| Oberlander, 2008 | inadequate or absent control group | EXCLUDED: Analysis of late versus early exposure to serotonin reuptake inhibitor (SRI) or effects of duration of gestational exposure => All pregnancies exposed to SRI => No adequate control group. |
Oberlander Br J Psychiatry 2008; 192:338-43 10.1192/bjp.bp.107.037101 |
| Gram, 2024 | inadequate or absent control group | EXCLUDED: Study on pattern of exposure, with continuation or discontinuation before or during pregnancy => Discontinuation group cannot be considered as unexposed because a % of exposed pregnancies => No adequate control group. |
Gram Psychiatry Res 2024; 342:116274 10.1016/j.psychres.2024.116274 |
| McElhatton, 1996 | case report or case series | EXCLUDED: This is a descriptive large case series, not an epidemiology study. Authors did not perform comparison with untreated controls. |
McElhatton Reprod Toxicol 1996; 10:285-94 10.1016/0890-6238(96)00057-3 |
| Wide, 2019 | other reason | EXCLUDED: 'As it is an ongoing randomized trial that has no preliminary results. Seventeen women are recruited. One child has been followed up at two years of age.' |
Wide, K. Reprod. Toxicol. 2019; 88:137-. 10.1016/j.reprotox.2019.05.023 |
| Andersson, 2004 | not relevant exposure | EXCLUDED: analysis according to illness. Medication use not assessed. |
Andersson Am. J. Epidemiol. 2004; 159:872-81 10.1093/aje/kwh122 |
| Hedegaard, 1993 | not relevant exposure | EXCLUDED: analysis of impact of psychological distress during pregnancy on the risk of preterm delivery, without analysis of medications. | |
| Hoffman, 2000 | not relevant exposure | EXCLUDED: analysis according to illness statut without data about treatment. | |
| Zimmer-Gembeck, 1996 | not relevant exposure | EXCLUDED: no data about antidepressants and SSRI. |
Zimmer-Gembeck Soc Sci Med 1996; 43:187-97 10.1016/0277-9536(95)00361-4 |
| Diego, 2009 | not relevant exposure | EXCLUDED: Women did not report taking antidepressants or other psychotropic medications during pregnancy. |
Diego Early Hum. Dev. 2009; 85:65-70 10.1016/j.earlhumdev.2008.07.002 |
| Heinonen, 1977 | not relevant exposure | EXCLUDED: not related to Selective serotonin reuptake inhibitor (SSRI) but older antidepressants. |
Heinonen OP, Slone D, Shapiro S. Littleton: Publishing Sciences Group, Inc; 1977. |
| Grieve, 2019 | not relevant exposure | EXCLUDED: analysis of 4 parameters of delta brushes (rate per minute (rate), amplitude of high frequency component (ampl), burst duration, i.e. width (width), and frequency of the high frequency oscillation), not relevant for metaPreg. |
Grieve Clin Neurophysiol 2019; 130:2019-2025 10.1016/j.clinph.2019.08.021 |
| van Wattum, 2023 | not relevant exposure | EXCLUDED: Analysis of SSRI and/or SNRI during pregnancy, without distinction between class or substances. | |
| Carter, 2012 | not in pregnancy | EXCLUDED: not related to pregnancy. |
Carter Int J Clin Pharm 2012; 34:658-66 10.1007/s11096-012-9661-z |
| Yang, 2018 | not about fetal exposure | EXCLUDED: Analysis related to paternal exposure ('we restricted the analyses to the children whose mothers neither received antidepressants during pregnancy nor had affective disorders'). | |
| Dayan, 2006 | not about fetal exposure | EXCLUDED: no analysis of treatments. |
Dayan Psychosom Med 2006; 68:938-46 10.1097/01.psy.0000244025.20549.bd |
| Orr, 2002 | not about fetal exposure | EXCLUDED: analysis according to illness. Medication use not assessed. | |
| Neggers, 2006 | not about fetal exposure | EXCLUDED: analysis according to illness. Medication use not assessed. |
Neggers Acta Obstet Gynecol Scand 2006; 85:277-85 10.1080/00016340600566121 |
| Rahman, 2004 | not about fetal exposure | EXCLUDED: analysis according to Maternal Depression and Disability, without consideration of treatments. |
Rahman Arch. Gen. Psychiatry 2004; 61:946-52 10.1001/archpsyc.61.9.946 |
| Steer, 1992 | not about fetal exposure | EXCLUDED: analysis according to illness. Medication use not assessed. |
Steer J Clin Epidemiol 1992; 45:1093-9 10.1016/0895-4356(92)90149-h |
| Copper, 1996 | not about fetal exposure | EXCLUDED: no analysis of treatments. |
Copper Am. J. Obstet. Gynecol. 1996; 175:1286-92 10.1016/s0002-9378(96)70042-x |
| Chung, 2001 | not about fetal exposure | EXCLUDED: no analysis of treatments. |
Chung Psychosom Med ; 63:830-4 10.1097/00006842-200109000-00017 |
| Dayan, 1999 | not about fetal exposure | EXCLUDED: no analysis of treatments. | |
| Dole, 2003 | not about fetal exposure | EXCLUDED: no analysis of treatments. | |
| Elsenbruch, 2007 | not about fetal exposure | EXCLUDED: no analysis of treatments. | |
| Evans, 2007 | not about fetal exposure | EXCLUDED: no analysis of treatments. |
Evans Br J Psychiatry 2007; 191:84-5 10.1192/bjp.bp.105.016568 |
| Li, 2009 | not about fetal exposure | EXCLUDED: analysis according to illness. Medication use not assessed. | |
| Paarlberg, 1999 | not about fetal exposure | EXCLUDED: analysis according to illness. Medication use not assessed. |
Paarlberg Br J Obstet Gynaecol 1999; 106:834-41 10.1111/j.1471-0528.1999.tb08406.x |
| Patel, 2006 | not about fetal exposure | EXCLUDED: analysis according to illness. Medication use not assessed. |
Patel Br J Psychiatry 2006; 188:284-5 10.1192/bjp.bp.105.012096 |
| Cliver, 1992 | not about fetal exposure | EXCLUDED: no analysis of treatments. | |
| Jesse, 2003 | not about fetal exposure | EXCLUDED: analysis of preterm according to Biophysical risk measures, psychosocial profile, without analysis of medications. |
Jesse Midwifery 2003; 19:191-202 10.1016/s0266-6138(03)00031-7 |
| Perkin, 1993 | not about fetal exposure | EXCLUDED: no analysis of treatments. |
Perkin Br J Obstet Gynaecol 1993; 100:629-34 10.1111/j.1471-0528.1993.tb14228.x |
| Rondó, 2003 | not about fetal exposure | EXCLUDED: analysis according to illness. Medication use not assessed. |
Rondo Eur J Clin Nutr 2003; 57:266-72 10.1038/sj.ejcn.1601526 |
| Unwin, 2013 | not relevant study design | EXCLUDED: 'The study compared the behavioral and developmental phenotype of children with ASD whose mothers used SSRIs during pregnancy with the phenotype for a tightly matched group of children with ASD whose mothers did not use SSRIs during pregnancy.' |
Unwin Front Hum Neurosci 2013; 7:606 10.3389/fnhum.2013.00606 |
| Oberlander b, 2008 | not relevant outcome | EXCLUDED: continuous variables (cortisol levels). |
Oberlander TF Early Hum Dev 2008;84:689-97 10.1016/j.earlhumdev.2008.06.008 |
| Hermansen, 2017 | not relevant outcome | EXCLUDED: continuous and inadequate variables (N2 amplitude, late slow wave, speeded/slow response times...). |
Hermansen TK Psychopharmacology (Berl) 2017;234:339-351 10.1007/s00213-016-4467-7 |
| Nezvalova-Henriksen, 2016 | not relevant outcome | EXCLUDED: continuous variables (birthweight and gestational age). Women using non-SSRI antidepressants (n=62) were excluded from the study. |
Nezvalova-Henriksen K Int J Epidemiol 2016;45:2018-2029 10.1093/ije/dyw049 |
| Ansah, 2019 | not relevant outcome | EXCLUDED: study of continuous variables (left ventricular dimensions and cardiac function parameters). | |
| Laine, 2003 | not relevant outcome | EXCLUDED: all outcomes are continuous (Apgar score, serotonergic symptom scores, umbilical vein monamine and metabolite concentrations, prolactin concentrations, ...). |
Laine Arch Gen Psychiatry 2003; 60:720-6 10.1001/archpsyc.60.7.720 |
| Maayan-Metzger, 2006 | not relevant outcome | EXCLUDED: all outcomes are continuous (Apgar score, hematocrit, platelet function, i.e parameters of surface coverage (SC) and average size (AS) evaluated with using a cone and platelet analyzer (CPA) device, ...). |
Maayan-Metzger Acta Haematol 2006; 115:157-61 10.1159/000090929 |
| Dubnov-Raz, 2012 | not relevant outcome | EXCLUDED: outcomes are continuous variables (weight, length, head circumference, tibia speed of sound, bone density, ...). |
Dubnov-Raz Early Hum Dev 2012; 88:191-4 10.1016/j.earlhumdev.2011.08.005 |
| de Jonge, 2015 | not relevant outcome | EXCLUDED: methodological publication without analysis related to the link between malformations and in utero exposure to medicines. |
de Jonge Drug Saf 2015; 38:1083-93 10.1007/s40264-015-0321-9 |
| Pawluski, 2009 | not relevant outcome | EXCLUDED: continuous variables (Apgar scores at 1 and 5 minutes, birth weight, head circumference, body length, gestational age, serum S100B levels, ...) and symptoms of poor neonatal adaptation reported but not by neonates. |
Pawluski Pediatrics 2009; 124:e662-70 10.1542/peds.2009-0442 |
| Ansah, 2018 | not relevant outcome | EXCLUDED: continuous variable (left and right ventricular diameter and length). |
Ansah, D.A. J. Am. Soc. Echocardiogr. 2018; 31:B36-. 10.1016/j.echo.2018.04.010 |
| Bar-Yosef, 2023 | not relevant outcome | EXCLUDED: Result expressed as a continuous variable ('Time to first void was longer in infants exposed to SSRI treatment (10.9 vs 9.4 hours, p=0.007)'). |
Bar-Yosef, Y. Eur. Urol. 2023; 83:S892-. 10.1016/S0302-2838(23)00673-5 |
| Oberlander, 2006 | data not abstractable | EXCLUDED: results not exploitable: raw data not provided (only incidence rate, without the numerator nor the denominator (number of neonates)) and no odd ratio or relative risk provided (only difference of incidence). |
Oberlander TF Arch Gen Psychiatry 2006;63:898-906 10.1001/archpsyc.63.8.898 |
| Lupattelli, 2018 | data not abstractable | EXCLUDED: results not extractable. |
Lupattelli J Am Acad Child Adolesc Psychiatry 2018; 57:200-208 10.1016/j.jaac.2017.12.010 |
| Vajda, 2020 | data not abstractable | EXCLUDED: data on citalopram and escitalopram not abstractable. |
Vajda Epilepsy Behav 2020; 103:106481 10.1016/j.yebeh.2019.106481 |
| El Marroun, 2017 | data not abstractable | EXCLUDED: data not extractable (authors provided B (Betas)). |
El Marroun J Psychopharmacol 2017; 31:346-355 10.1177/0269881116665335 |
| Weikum, 2013 | data not abstractable | Overlapping of some outcomes (Mental and Psychomotor Development Index) with Oberlander 2004 which include a little more pregnancies, thus these outcomes not reported for Weikum 2013. Results on mother–infant interactions not extractable. |
Oberlander J Clin Psychiatry 2004; 65:230-7 10.4088/jcp.v65n0214 Weikum Infant Behav Dev 2013; 36:485-93 10.1016/j.infbeh.2013.04.001 |
| Rotem-Kohavi b, 2019 | data not abstractable | EXCLUDED: data not extractable (resting-state functional magnetic resonance imaging). |
Rotem-Kohavi Biol Psychiatry Cogn Neurosci Neuroimaging 2019; 4:39-49 10.1016/j.bpsc.2018.08.004 |
| Podrebarac, 2017 | data not abstractable | EXCLUDED: data not extractable. |
Podrebarac Neuroscience 2017; 342:252-262 10.1016/j.neuroscience.2016.11.025 |
| Misri, 2010 | data not abstractable | EXCLUDED: Authors mentioned 'exposure to prenatal SSRIs and SNRIs was not a significant predictor in any of the models (allPs > 0.200)' but no extractable data. |
Misri Can J Psychiatry 2010; 55:222-8 10.1177/070674371005500405 |
| Richardson, 2020 | data not abstractable | EXCLUDED: no OR provided and insufficient raw data (number of exposure to citalopram (n=93), sertraline (n=51), and fluoxetine (n=45) reported in neural tube defect (NTD) cases but not in controls). |
Richardson, J.L. Reprod. Toxicol. 2020; 97:11-. 10.1016/j.reprotox.2020.04.047 |
| Moreau, 2023 | data not abstractable | EXCLUDED: Results not usable here because authors provided coefficients of continuous variables, without sufficient data to express an OR. Use of SSRIs: sertraline n = 118, fluoxetine n = 68, escitalopram n = 54. |
Moreau, A.L. Biol. Psychiatry Glob. Open Sci. 2023; 3:243-. 10.1016/j.bpsgos.2022.02.005 |
| Kaltenbach, 2012 | data not abstractable | EXCLUDED: Data not extractable (correlation coefficient). |
Kaltenbach Addiction 2012; 107 Suppl 1:45-52 10.1111/j.1360-0443.2012.04038.x |
| Christensen, 2021 | data not abstractable | EXCLUDED: Aberrant values obtained using conversion of continuous values to OR (due to unmet assumptions of continuous distribution) => additional analyses of the study (including breaking down by type of antidepressants) not available (author's reply). |
Christensen JAMA 2021; 326:1725-1735 10.1001/jama.2021.17380 |
| Burian, 2016 | data not abstractable | EXCLUDED: Data not abstractable ('The offspring of SSRI had higher rate of LBW (p<0.05 respect to healthy controls)'). | |
| Selmer, 2016 | same data already obtained by other studies | EXCLUDED: Reanalyze of the dataset used by Furu 2015 (the original study). |
Selmer Pharmacoepidemiol Drug Saf 2016; 25:1160-1169 10.1002/pds.4033 |
| Berard, 2006 | same data already obtained by other studies | EXCLUDED: an entire publication, more detailed that this abstract was published by Cole 2007. |
Bérard Birth Defects Res A Clin Mol Teratol. 2006;76:335. Abstract |
| Handal b, 2016 | same data already obtained by other studies | EXCLUDED: sub-analysis of data published by Skurtveit 2014. |
Handal J Clin Psychopharmacol 2016; 36:333-9 10.1097/JCP.0000000000000519 |
| Skurtveit, 2013 | same data already obtained by other studies | EXCLUDED: re-analysis of data published by Kieler 2012. |
Skurtveit J Clin Epidemiol 2013; 66:964-72 10.1016/j.jclinepi.2013.02.011 |
| Almeida, 2016 | same data already obtained by other studies | Overlapping: same databases, outcomes and study period that data published by Nakhai-Pour 2010, which included more pregnancies than Almeida 2016 and analyzed individual SSRI. Thus Nakhai-Pour 2010 reported rather than Almeida 2016. |
Almeida Epidemiology 2016; 27:538-46 10.1097/EDE.0000000000000484 |
| Reis, 2013 | same data already obtained by other studies | EXCLUDED: Totally overlapped by Reis 2010 (1995 - 2007) and Furu 2015 (2006-2010 with other countries). | |
| Malm, 2012 | no specific data | EXCLUDED: publication on the protocol of a study (without results). | |
| Hayes, 2012 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis performed for antidepressants as a whole without distinction between SSRI and non SSRI. |
Hayes RM Am J Obstet Gynecol 2012;207:49.e1-9 10.1016/j.ajog.2012.04.028 |
| Nulman, 2015 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of women were exposed to selective serotonin reuptake inhibitor (citalopram, paroxetine, sertraline, fluoxetine) and/or serotonin-norepinephrine reuptake (venlafaxine) without distinction (the % of venlafaxine not available). |
Nulman I J Clin Psychiatry 2015;76:e842-7 10.4088/JCP.14m09240 |
| Partridge, 2016 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Analysis of serotonin reuptake inhibitor (SRI) as a whole (selective SRIs and serotonin/norepinephrine reuptake inhibitors), without distinction of SSRIs. |
Partridge MC J Pediatr 2016;175:144-149.e1 10.1016/j.jpeds.2016.04.065 |
| Ogunyemi, 2018 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: treatments analyses as a whole without distinction between treatments (SSRIs, benzodiazepines, other antidepressants (10.3%) and other medications including serotonin–norepinephrine reuptake inhibitors, antiepileptics and antipsychotics). | |
| Boucher, 2008 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressants as a whole (including 78% (57/73) of selective serotonin reuptake inhibitor) without distinction between classes of antidepressants. |
Boucher J Clin Psychopharmacol 2008; 28:334-9 10.1097/JCP.0b013e318173aa2e |
| Chun-Fai-Chan, 2005 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of 'buproprion' and 'other antidepressants', without distinction between antidepressants. |
Chun-Fai-Chan Am. J. Obstet. Gynecol. 2005; 192:932-6 10.1016/j.ajog.2004.09.027 |
| Djulus, 2006 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Analysis of 'other antidepressants' (such as selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, or tricyclic antidepressants) as a whole. |
Djulus J Clin Psychiatry 2006; 67:1280-4 10.4088/jcp.v67n0817 |
| Einarson, 2003 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of 'Trazodone and Nefazodone' and 'other nonteratogenic antidepressants' without distinction between class of antidepressants. |
Einarson Can J Psychiatry 2003; 48:106-10 10.1177/070674370304800207 |
| Hammad, 2009 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Assessment of the risk of PPHN in association with maternal exposure to SSRIs and non-SSRI antidepressant, without specific result for SSRI. | |
| Berle, 2005 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of anxiolytic and antidepressant medication as a whole, without distinction between substances or class of substances. |
Berle Arch Womens Ment Health 2005; 8:181-9 10.1007/s00737-005-0090-z |
| Gavin, 2010 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of psychotropic medications as a whole, without distinction of selective serotonin reuptake inhibitors (SSRI). |
Gavin Womens Health Issues ; 19:325-34 10.1016/j.whi.2009.05.004 |
| Haas, 2005 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis according illness without data on treatment. |
Haas Arch Pediatr Adolesc Med 2005; 159:58-63 10.1001/archpedi.159.1.58 |
| Bandoli, 2020 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medication as a whole, without distinction between substances or class of substances (69.9% had SSRI monotherapy, 6.6% had SNRI monotherapy, and 8.9% had bupropion monotherapy). | |
| Wolgast, 2021 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medication as a whole, without distinction between substances or class of substances. |
Wolgast Eur J Obstet Gynecol Reprod Biol 2021; 257:42-50 10.1016/j.ejogrb.2020.11.062 |
| Heller, 2017 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of serotonergic antidepressants (SSRIs, TCAs or SNRIs) as a whole, without distinction between substances or class of substances. |
Heller BMC Pregnancy Childbirth 2017; 17:166 10.1186/s12884-017-1334-4 |
| Singal, 2020 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medication as a whole, without distinction between substances or class of substances (SSRI or SNRI). | |
| Grzeskowiak, 2016 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medication as a whole, without distinction between substances or class of substances. |
Grzeskowiak BJOG 2016; 123:1919-1928 10.1111/1471-0528.13611 |
| Sivathamboo, 2018 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medication as a whole, without distinction between substances or class of substances (SSRI, SNRIs, TCAs, other atypical ADDs). Some analysis of specific SSRI (co-exposed to AED) without adequate control group. | |
| Grzeskowiak, 2016 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medication as a whole, without distinction between substances or class of substances (SSRI, SNRI monotherapy, TCA, other antidepressants). |
Grzeskowiak BJOG 2016; 123:1929-1936 10.1111/1471-0528.13612 |
| Frayne, 2017 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medication as a whole, without distinction between substances or class of substances (SSRI or SNRI). |
Frayne Aust N Z J Obstet Gynaecol 2017; 57:526-532 10.1111/ajo.12621 |
| Venkatesh, 2017 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medication as a whole, without distinction between substances or class of substances. | |
| Yonkers, 2012 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of SRIs as a whole without distinction between class or substance (dulotexine and venlafaxine (non-SSRI) represents more than 10% of SRI: 37/320). |
Yonkers Epidemiology 2012; 23:677-85 10.1097/EDE.0b013e31825838e9 |
| Einarson, 2010 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medication as a whole, without distinction between substances or class of substances. | |
| Einarson, 2011 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medication as a whole, without distinction between substances or class of substances. | |
| Yonkers, 2017 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of serotonin reuptake inhibitor (SRI) as a whole, without distinction between substances or class of substances. |
Yonkers JAMA Psychiatry 2017; 74:1145-1152 10.1001/jamapsychiatry.2017.2733 |
| Laine, 2019 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medication as a whole, without distinction between substances or class of substances (N06A or N06C). | |
| Kim, 2016 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of serotonin reuptake inhibitor (SRI) as a whole, without distinction of substances or selective serotonin reuptake inhibitor (SSRI) class. |
Kim J Psychiatr Res 2016; 73:79-85 10.1016/j.jpsychires.2015.11.005 |
| Lindqvist, 2014 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: SSRI exposed group included SSRI and other non-SSRI substances (alaproclate, citalopram, escitalopram, etoperidon, fluoxetin, fluvoxamin, paroxetin, sertralin or zimelidin), without distinction between substances. |
Lindqvist J Thromb Haemost 2014; 12:1986-92 10.1111/jth.12757 |
| Castro, 2016 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medication as a whole, without distinction between substances or class of substances. No overlapping with Clements 2014: 'Mother − child pairs included in our previous report were excluded'. | |
| Pedersen, 2013 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressants as a whole, without distinction between substance or class (antidepressants included > 10% of non-SSRI). Data not shown for SSRI. |
Pedersen Acta Psychiatr Scand 2013; 127:126-35 10.1111/acps.12032 |
| Suri, 2011 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medication as a whole, without distinction between substances or class of substances (36% sertraline, 38%fluoxetine, and other antidepressants). | |
| Hurault-Delarue, 2016 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medication as a whole, without distinction between substances or class of substances (n=173: amitriptyline (n=32), paroxetine (n=32), fluoxetine (n=30), venlafaxine...). |
Hurault-Delarue Fundam Clin Pharmacol 2016; 30:476-82 10.1111/fcp.12209 |
| Santucci, 2014 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Serotonin Reuptake Inhibitors group (n=41) included more than 10% of the nonSSRI venlafaxine (sertraline (n = 15), fluoxetine (n = 11), escitalopram (n = 7), citalopram (n = 5), fluvoxamine (n = 1), paroxetine (n = 1), and venlafaxine (n = 5)). |
Santucci J Clin Psychiatry 2014; 75:1088-95 10.4088/JCP.13m08902 |
| Mortensen, 2003 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medication as a whole, without distinction between substances or subclass of substances. |
Mortensen Eur J Epidemiol 2003; 18:769-71 10.1023/a:1025306304635 |
| Austin, 2013 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: The exposed group included 26 SSRI, 5 Dothiepin and 4 Venlafaxine among 35 exposures. Non SSRI represents 25% of the exposed group. | |
| Hanley, 2013 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of serotonin reuptake inhibitor (SRI) (paroxetine (n = 4), fluoxetine (n = 3), sertraline (n = 5), venlafaxine (n = 12; 39%), and citalopram (n=7)) as a whole without distinction between substances or SSRI class. |
Hanley Early Hum Dev 2013; 89:519-24 10.1016/j.earlhumdev.2012.12.012 |
| Johnson, 2012 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressants as a whole, without distinction between substance or subclass of Selective serotonin reuptake inhibitors (SSRIs). |
Johnson Arch Gen Psychiatry 2012; 69:787-94 10.1001/archgenpsychiatry.2012.160 |
| Galbally, 2017 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medication as a whole, without distinction between substances or class of substances (40 (78%) women used an SSRI, whereas 11 (22%) women used a SNRI). | |
| Galbally, 2015 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medication as a whole, without distinction between substances or subclass of substances (32 antidepressants: 27 SSRIs (84%), 3 SNRIs, 1 TCA and 1 noradrenergic and specific serotonergic antidepressant (NaSSA)). |
Galbally Aust N Z J Psychiatry. 2015;49(7):642–650 10.1177/0004867415569800 |
| Hermansen, 2016 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medication as a whole, without distinction between substances or subclass of substances (20/28 SSRI, 7/28 SNRI and 1/28 mirtazapine). |
Hermansen Psychopharmacology (Berl) 2016; 233:1523-35 10.1007/s00213-016-4248-3 |
| Galbally, 2011 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medication as a whole, without distinction between substances or subclass of substances (15 SSRI, 4 SNRI and 2 NaSSA). | |
| Weikum, 2012 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of serotonin reuptake inhibitors (SRIs) as a whole, without distinction between substances or subclass of substances (19SSRI ; 13 SNRI). |
Weikum Proc Natl Acad Sci U S A 2012; 109 Suppl 2:17221-7 10.1073/pnas.1121263109 |
| Johnson, 2016 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of serotonin reuptake inhibitors (SRIs) as a whole, without distinction between substances or subclass of substances (83SSRI ; 23 SNRI). |
Johnson J Clin Psychiatry 2016; 77:e176-82 10.4088/JCP.14m09348 |
| Bandoli, 2018 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medication as a whole, without distinction between substances or subclass of substances (SSRI and other antidepressants). |
Bandoli Arch Womens Ment Health 2018; 21:411-419 10.1007/s00737-018-0809-2 |
| Rotem-Kohavi a, 2019 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of SRI medication as a whole, without distinction between substances or subclass of substances ('Women treated with SSRIs and also with SNRIs were included... we will not differentiate between these two pharmacological treatments.'). |
Rotem-Kohavi Depress Anxiety 2019; 36:753-765 10.1002/da.22906 |
| Salzwedel, 2020 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: data not extractable or without distinction between substances or subclass of substances. |
Salzwedel Hum Brain Mapp 2020; 41:4789-4803 10.1002/hbm.25158 |
| Kieviet, 2017 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medications as a whole, without distinction between substances or subclass of substances (paroxetine, fluoxetine, citalopram, sertraline, velanfaxine, fluvoxamine, mirtazapine, bupropion). |
Kieviet BMC Pregnancy Childbirth 2017; 17:23 10.1186/s12884-016-1184-5 |
| Weikum b, 2013 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of serotonin reuptake inhibitor (SRI) antidepressant as a whole, without distinction between substances or subclass of substances (SSRI in particular). |
Weikum Front Cell Neurosci 2013; 7:180 10.3389/fncel.2013.00180 |
| Eriksen, 2015 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressants or anxiolytics (N06A or N05B) as a whole, without distinction between substances or subclass of substances (SSRI and other antidepressants). |
Eriksen Acta Obstet Gynecol Scand 2015; 94:501-7 10.1111/aogs.12611 |
| De Las Cuevas, 2007 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis according illness without analysis according treatment. |
De Las Cuevas Pharmacoepidemiol Drug Saf 2007; 16:1018-23 10.1002/pds.1401 |
| Yamamoto-Sasaki, 2019 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Analysis of antidepressant medication as a whole, without distinction between substances or subclass of substances (77.9% had SSRI, 5.6% had SNRI monotherapy, and 25.6% had antidepressants of other classes). |
Yamamoto-Sasaki Matern Health Neonatol Perinatol 2019; 5:1 10.1186/s40748-018-0096-y |
| Ferreira, 2007 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Forty-six (60.5%) were taking paroxetine, 10 (13.2%) fluoxetine, 9 (11.8%) venlafaxine, 6 (8%) citalopram, 3 (3.9%) sertraline, and 2 (2.6%) fluvoxamine => More than 10% of SNRI => Not considered as SSRI. | |
| Campbell, 2021 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: In this study, SRI antidepressants included any selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptakeinhibitor (SNRI) were studied as a whole without distinction between SSRI and SNRI. |
Campbell Front Psychiatry 2021; 12:680177 10.3389/fpsyt.2021.680177 |
| Lupattelli, 2021 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: SSRIs (sertraline, fluoxetine, paroxetine, citalopram, escitalopram, fluvoxamine) and SNRIs (venlafaxine, duloxetine) analyzed together without distinction between SSRI and SNRI. | |
| Melov, 2021 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: SSRIs (fluoxetine, sertraline, paroxetine, escitalopram, fluvoxamine) and SNRIs (desvenlafaxine, duloxetine) analyzed together without distinction between SSRI and SNRI. | |
| Dolk, 2020 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of SSRIs (Citalopram, Escitalopram, Fluoxetine, and Sertraline) and SNRI (Mirtazapine and Venlafaxine) as a whole, without distinction between subclass or treatments. |
Dolk PLoS One 2020; 15:e0227908 10.1371/journal.pone.0227908 |
| Chouchana, 2021 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant as a whole, without distinction between class/substances. |
Chouchana, L. Fundam. Clin. Pharmacol. 2021; 35:179-. 10.1111/fcp.12670 |
| Sjaarda, 2019 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressant medication as a whole, without distinction between substances or subclass of substances (SSRI and other antidepressants). |
Sjaarda, L.A. Fertil. Steril. 2019; 112:e2-. 10.1016/j.fertnstert.2019.07.139 |
| Bakhireva, 2022 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Analysis of serotonin reuptake inhibitors (SRIs) as a whole, without distinction between SSRIs and SNRIs (sertraline (44.4%), fluoxetine (40.7%) and duloxetine (37.0%)). |
Bakhireva Pediatr Res 2022; 91:867-873 10.1038/s41390-021-01756-4 |
| Gustafsson, 2018 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Analysis of serotonin reuptake inhibitors (SRIs) as a whole, without distinction between SSRIs and SNRIs (no details on the proportion of SSRI and SNRIs). |
Gustafsson Dev Psychopathol 2018; 30:773-785 10.1017/S0954579418000639 |
| Videman, 2017 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Analysis of serotonin reuptake inhibitors (SRIs) as a whole, without distinction between SSRIs and SNRIs (22 SRI exposures: 20 SSRI and/or 4 SNRIs). |
Videman Cereb Cortex 2017; 27:3208-3216 10.1093/cercor/bhw153 |
| Hanley, 2015 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Analysis of serotonin reuptake inhibitors (SRIs) as a whole, without distinction between SSRIs and SNRIs (44 SRI exposures: 34 SSRI and 10 SNRIs). | |
| Smearman, 2020 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Analysis of serotonin reuptake inhibitors (SRIs) as a whole, without distinction between SSRIs and SNRIs (sertraline and fluoxetine the most common, but no other details). |
Smearman Dev Psychopathol 2020; 32:21-30 10.1017/S0954579418001372 |
| Singh, 2022 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Antidepressants analysed as a whole, without distinction between classes (52 exposed to Sertaline, 25 to Venlafexine, 19 to Paroxetine,18 to Fluoxetine, 18 to the combination of Venlafexine and Mirtazepie and 18 to Escitalopram). |
Singh, P. NeuroQuantology 2022; 20:4718-. 10.14704/nq.2022.20.8.NQ44499 |
| Chouchana, 2022 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of antidepressants as a whole, without distinction between classes (abstract). |
Chouchana, L. Fundam. Clin. Pharmacol. 2022; 36:31-. 10.1111/fcp.12786 |
| Parpinel, 2022 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Analysis of pharmacological treatments as a whole (SSRI, SNRI, benzodiazepines, ...) without distinction between classes. |
Parpinel, G. J. Clin. Med. 2022; 11:153-. 10.3390/jcm11061486 |
| Viguera, 2023 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: analysis of mothers who had taken an SSRI and/or SNRI during their pregnancy, as a whole, without distinction between SSRI and SNRI. | |
| Michel, 2023 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: OR based on dichotomized variable only provided for maternal QT-prolonging drugs as a whole without distinction between treatments. Results for PPIs, SSRIs, and dimenhydrinate, only provided as a continuous variable (mean postnatal QTc). |
Michel Front Pharmacol 2023; 14:1193317 10.3389/fphar.2023.1193317 |
| Michielsen, 2014 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Analysis of Medications (SSRI, non-SSRI antidepressants, antipsychotics and mood stabilizers) as a whole without distinction between subclass or treatments. |
Michielsen Neuropsychiatr Dis Treat 2014; 10:13-8 10.2147/NDT.S53430 |
| Zusman, 2023 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Analysis of serotonin reuptake inhibitors (SRIs) as a whole, without distinction between SSRIs and SNRIs (paroxetine (31%), venlafaxine (27%), citalopram (17%), fluoxetine (15%), ... | |
| Leibovitch, 2013 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Analysis of serotonin reuptake inhibitors (SRIs) as a whole, without distinction between SSRIs and SNRIs (fluoxetine, paroxetine or citalopram, sertaline, fluvoxamine or venlafaxine). | |
| Rommel, 2024 | Studies without separate analysis of the considered drug/class from other drugs/class | EXCLUDED: Analysis of antidepressant medication as a whole, without distinction between substances or subclass of substances (SSRI and other antidepressants). |
Rommel Acta Psychiatr Scand 2024; 150:344-354 10.1111/acps.13636 |
| Einarson, 2006 | Review articles, letter to editor, editorial, comments | EXCLUDED: commentary and analysis of published studied. | |
| Williams, 2005 | Review articles, letter to editor, editorial, comments | EXCLUDED: Comments on a published study. | |
| Clark, 2016 | Review articles, letter to editor, editorial, comments | EXCLUDED: Mini commentary. | |
| Furu b, 2015 | Review articles, letter to editor, editorial, comments | EXCLUDED: Erratum of the article of Furu 2015 (erratum did not concern data implemented in Metapreg). | |
| Kowalik, 2016 | Review articles, letter to editor, editorial, comments | EXCLUDED: Meta-analysis without quantitative data ('The results of the analysis showed a significant association between the use of SSRIs in pregnancy and the development of CHD in children.') |
Kowalik, E. Pharmacotherapy 2016; 36:e302-. 10.1002/phar.1877 |
| Cesta, 2016 | efficacy rather than safety aims | EXCLUDED: Study on the efficacy of treatment, including the miscarriage outcome that is studied as an efficacy criteria rather than a safety one. |
Cesta Fertil Steril 2016; 105:1594-1602.e3 10.1016/j.fertnstert.2016.01.036 |
-
About
-
Master protocol
-
Browse exposition
-
RSS
-
Made with in Lyon
-
Contact us
-
Privacy policy
-
